CELL BIOLOGY AND METABOLISM
The Rate of Internalization of the Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is Enhanced by Multivalent Ligand Binding*

https://doi.org/10.1074/jbc.274.2.1164Get rights and content
Under a Creative Commons license
open access

The cation-independent mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) undergoes constitutive endocytosis, mediating the internalization of two unrelated classes of ligands, mannose 6-phosphate (Man-6-P)-containing acid hydrolases and insulin-like growth factor II (IGF-II). To determine the role of ligand valency in M6P/IGF-II receptor-mediated endocytosis, we measured the internalization rates of two ligands, β-glucuronidase (a homotetramer bearing multiple Man-6-P moieties) and IGF-II. We found that β-glucuronidase entered the cell ∼3–4-fold faster than IGF-II. Unlabeled β-glucuronidase stimulated the rate of internalization of125I-IGF-II to equal that of125I-β-glucuronidase, but a bivalent synthetic tripeptide capable of occupying both Man-6-P-binding sites on the M6P/IGF-II receptor simultaneously did not. A mutant receptor with one of the two Man-6-P-binding sites inactivated retained the ability to internalize β-glucuronidase faster than IGF-II. Thus, the increased rate of internalization required a multivalent ligand and a single Man-6-P-binding site on the receptor. M6P/IGF-II receptor solubilized and purified in Triton X-100 was present as a monomer, but association with β-glucuronidase generated a complex composed of two receptors and one β-glucuronidase. Neither IGF-II nor the synthetic peptide induced receptor dimerization. These results indicate that intermolecular cross-linking of the M6P/IGF-II receptor occurs upon binding of a multivalent ligand, resulting in an increased rate of internalization.

Cited by (0)

*

This work was supported by National Institutes of Health Grant CA08759-30 (to S. K.), Postdoctoral Training Grant T32 HL07088 (to L. S. A.), and Grant DK42667 (to N. M. D.) and by Medical Scientist Training Program Training Grant T32 GM07200 (to S. J. Y.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

Present address: Dept. of Medicine, Duke University Medical Center, Durham, NC 27706.

Performed this work during the tenure of an Established Investigatorship from the American Heart Association.